Bio Green Med Solution

Cyclacel's business model is centered on intensive research and development to create a diversified portfolio of novel drug candidates that address unmet medical needs in oncology and hematology. The company's revenue is primarily generated through collaborations and R&D activities, as it advances its pipeline through rigorous clinical trials to evaluate safety and efficacy. The company's strategy involves advancing its oncology programs internally before seeking partnerships to maximize commercial returns.

The company's pipeline is built on its expertise in cell cycle biology, transcriptional regulation, and mitosis. Key clinical-stage product candidates include Fadraciclib (CYC065), an orally available inhibitor of CDK2 and CDK9, and Plogosertib (CYC140), a selective PLK1 inhibitor. These candidates are being evaluated in mid-stage clinical trials for treating solid tumors, lymphomas, and hematological malignancies. Cyclacel aims to overcome cancer's resistance mechanisms by suppressing them and reactivating the body's natural cell death processes. The company retains worldwide marketing rights for its prescription candidates.